The MI paradox of risk scores, the CELEBRATE trial of a new subcutaneous glycoprotein IIb/IIIA inhibitor (with its funny endpoint), the SURPASS CVOT trial, and the bad story of andexanet alfa are the topics John Mandrola, MD, discusses in this week's podcast.
This podcast is intended for healthcare professionals only.
To read a partial transcript or to comment, visit:
https://www.medscape.com/twic
I What do risk scores mean for individuals? Or perhaps a better question: Is a first MI preventable?
- Limitations of Screening in Predicting First MI https://www.jacc.org/doi/10.1016/j.jacadv.2025.102361
- Sudden Death Due to Cardiac Arrhythmias https://www.nejm.org/doi/abs/10.1056/NEJMra000650
- UMC Amsterdam group (EHJ) https://academic.oup.com/eurheartj/article/46/38/3762/8181058
II CELEBRATE Trial
- CELEBRATE Trial https://evidence.nejm.org/doi/full/10.1056/EVIDoa2500268
III SURPASS CVOT Trial Published
Aug 01, 2025 This Week in Cardiology Podcast
https://www.medscape.com/viewarticle/1002781
- SURPASS-CVOT Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2505928
- REWIND Trial 10.1016/S0140-6736(19)31149-3 External Link
IV FDA Pulls Andexanet Alfa From the Market
- ANNEXA 4 https://www.nejm.org/doi/10.1056/NEJMoa1814051
- ANNEXA I https://www.nejm.org/doi/full/10.1056/NEJMoa2313040
- Richard Buka Tweet https://x.com/richardbuka/status/2001045834050216327?s=20
V Mandrola's Top Cardiovascular Stories of 2025
https://www.medscape.com/viewarticle/mandrolas-top-10-cardiovascular-stories-2025-2025a1000yuh
You may also like:
The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington
Questions or feedback, please contact news@medscape.net
